February 18, 2018 1:37 PM ET

Life Sciences Tools and Services

Company Overview of Yumanity Therapeutics Inc.

Company Overview

Yumanity Therapeutics Inc. identifies and develops disease-modifying therapies for neurodegenerative diseases caused by protein misfolding. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform, in which neurons produced from the stem cells of patients with disease-causing genetic mutations are used to validate the molecules discovered in yeast; and a drug-target identification platform that exploits the power of yeast genetics and protein network analyses to elucidate mechanisms of action for pathology correcti...

790 Memorial Drive

Suite 2C

Cambridge, MA 02139

United States

Founded in 2014

Phone:

617-409-5300

Key Executives for Yumanity Therapeutics Inc.

Chairman and Chief Executive Officer
Age: 57
Scientific Co-Founder & Senior Advisor of Discovery Biology
Scientific Co-Founder & Associate Director of Discovery Biology
Scientific Co-Founder & Associate Director of Discovery Biology
Chief Business Officer
Compensation as of Fiscal Year 2017.

Yumanity Therapeutics Inc. Key Developments

Yumanity Therapeutics Inc. Presents at Neuroscience Innovation Forum, Jan-07-2018 01:50 PM

Yumanity Therapeutics Inc. Presents at Neuroscience Innovation Forum, Jan-07-2018 01:50 PM. Venue: Marines' Memorial Club, San Francisco, California, United States. Speakers: Kenneth Rhodes, Chief Scientific Officer.

Yumanity Therapeutics Inc. Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 through Sep-29-2017

Yumanity Therapeutics Inc. Presents at Cambridge Healthtech Institute's 15th Annual Discovery on Target, Sep-25-2017 through Sep-29-2017. Venue: The Westin Copley Place, Boston, Massachusetts, United States. Presentation Date & Speakers: Sep-28-2017, Jeff Piotrowski, Principal Scientist, Target Identification, Robert Scannevin, Vice President of Discovery Biology.

Yumanity Therapeutics Inc. Presents at Boston CEO Conference, May-30-2017 01:20 PM

Yumanity Therapeutics Inc. Presents at Boston CEO Conference, May-30-2017 01:20 PM. Venue: Four Season Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Kenneth Rhodes, Chief Scientific Officer.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Yumanity Therapeutics Inc., please visit www.yumanity.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.